Arovella Therapeutics Limited (ASX:ALA) has disclosed a change in the relevant interests of director David John Williams, following an on-market purchase of 199,495 ordinary shares on 12 November 2026 at a price of $0.051690 per share, acquired through Moggs Creek Pty Ltd ATF Moggs Creek Superannuation Fund.

Key Points

  • Director David John Williams acquired 199,495 ordinary shares on-market on 12 November 2026 at $0.051690 per share
  • The shares were acquired indirectly through Moggs Creek Pty Ltd ATF Moggs Creek Superannuation Fund
  • Following the transaction, Moggs Creek Pty Ltd ATF Moggs Creek Superannuation Fund holds 199,495 ordinary shares and 8,000,000 performance rights
  • Lawn Views Pty Ltd ATF Angela Williams Family Trust continues to hold 200,000 ordinary shares, unchanged
  • The trade did not occur during a closed period requiring prior written clearance

On-Market Share Purchase by Director David John Williams

According to the filing lodged with ASX under Listing Rule 3.19A.2, director David John Williams made an indirect on-market purchase of 199,495 ordinary shares in Arovella Therapeutics Limited on 12 November 2026. The consideration paid was $0.051690 per share. The acquiring entity is Moggs Creek Pty Ltd ATF Moggs Creek Superannuation Fund, in which Williams holds the power to exercise or control the exercise of the right to vote or dispose of shares. No securities were disposed of as part of this transaction.

Post-Transaction Security Holdings Across Associated Entities

Following the change, Moggs Creek Pty Ltd ATF Moggs Creek Superannuation Fund holds 199,495 ordinary shares and 8,000,000 performance rights in Arovella Therapeutics. The separately disclosed entity, Lawn Views Pty Ltd ATF Angela Williams Family Trust, retains its existing holding of 200,000 ordinary shares, with no change recorded for that entity in this notice. Williams holds an indirect interest in both entities, with the power to exercise or control voting and disposal rights over the securities held within each.

Closed Period and Contractual Interest Disclosures

The filing confirms that the on-market purchase was not conducted during a closed period in which prior written clearance was required. As a result, the questions relating to written clearance and the date of such clearance are recorded as not applicable. Additionally, Part 2 of the filing, covering any change of the director's interests in contracts, discloses no relevant contractual interests, with all fields in that section recorded as not applicable. The previous director's interest notice for David John Williams was dated 6 November 2026.